Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (561-570 of 610) with videos related to

Pageof 61
Sort By:
Leukemia & Lymphoma|July 28, 2016
Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of TechniqueF J Giles, C D Lord, E J Gaminarai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2019
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage ResponseLi Ding, Vijay S Madamsetty, Spencer Kiers, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Biochemical and Biophysical Research Communications|September 11, 2012
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcomaJinu Abraham, Ying Xuan Chua, Jason M Glover, et al.
EMBO Molecular Medicine|September 28, 2019
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancerYuqian Yan, Jian Ma, Dejie Wang, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
Oncotarget|May 4, 2018
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancerCesar August Santa-Maria, Taigo Kato, Jae-Hyun Park, et al.
Blood|February 25, 2006
Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
JCO Precision Oncology|September 11, 2019
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsB A Carneiro, K A Collier, R J Nagy, et al.
Investigational New Drugs|April 27, 2011
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemiaSimona Lapusan, Maria B Vidriales, Xavier Thomas, et al.
Pageof 61

Showing results (561-570 of 610) with videos related to

Sort By:
Pageof 61
Leukemia & Lymphoma|July 28, 2016
Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of TechniqueF J Giles, C D Lord, E J Gaminarai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2019
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage ResponseLi Ding, Vijay S Madamsetty, Spencer Kiers, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Biochemical and Biophysical Research Communications|September 11, 2012
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcomaJinu Abraham, Ying Xuan Chua, Jason M Glover, et al.
EMBO Molecular Medicine|September 28, 2019
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancerYuqian Yan, Jian Ma, Dejie Wang, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
Oncotarget|May 4, 2018
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancerCesar August Santa-Maria, Taigo Kato, Jae-Hyun Park, et al.
Blood|February 25, 2006
Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
JCO Precision Oncology|September 11, 2019
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsB A Carneiro, K A Collier, R J Nagy, et al.
Investigational New Drugs|April 27, 2011
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemiaSimona Lapusan, Maria B Vidriales, Xavier Thomas, et al.
Pageof 61